Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tropisetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 9/20 | 1.00 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 7/20 | 1.00 |
| ▸ | HTR3B known ✓ | O95264 | 7/20 | 1.00 |
| ▸ | HTR3D known ✓ | Q70Z44 | 7/20 | 1.00 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 7/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CHRNA7 | P36544 | 3/20 | 1.00 |
| ▸ | CHRNA1 | P02708 | 2/20 | 1.00 |
| ▸ | CHRNG | P07510 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CHRNB1 | P11230 | 2/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 2/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 2/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 2/20 | 1.00 |
| ▸ | CHRND | Q07001 | 2/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tropisetron SCHEMBL18297 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL18299 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL29405651 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL3953452 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL17766649 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL31061471 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL29930627 | 1.00 | HTR3A (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL6273985 | 0.99 | APEX1 (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL669358 | 0.99 | APEX1 (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Tropisetron SCHEMBL133873 | 0.99 | APEX1 (1.00) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1239882-B1 | FORMULATIONS OF ADENOSINE A1 AGONISTS AND 5HT3 AGONISTS | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | claimed |
| US-20030018008-A1 | Formulations of adenosine a1 agonists | BOUNTRA CHARANJIT (GB) | 2003-01-23 | — | — | US | claimed |
| EP-0804196-B1 | USE OF SEROTONIN ANTAGONISTS (5HT 3) FOR TREATING FIBROMYALGIA | NOVARTIS AG (CH) | 2002-10-02 | — | — | EP | claimed |
| US-20020035057-A1 | Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions | RICHTER VIRGINIA PACT (US) | 2002-03-21 | — | — | US | claimed |
| US-5773436-A | Use of serotonin antagonists for treating fibromyalgia | NOVARTIS AG (CH) | 1998-06-30 | — | — | US | claimed |
| EP-0804196-A1 | USE OF SEROTONIN ANTAGONISTS (5HT 3?) FOR TREATING FIBROMYALGIA | Novartis AG (CH) | 1997-11-05 | — | — | EP | claimed |
| US-5530008-A | USEFUL FOR TREATING ANXIETY DISORDER AND AGORAPHOBIA | SANDOZ LTD. (CH) | 1996-06-25 | — | — | US | claimed |
| WO-1995027490-A1 | USE OF SEROTONIN ANTAGONISTS (5HT3) FOR TREATING FIBROMYALGIA | SANDOZ LTD. (CH) | 1995-10-19 | — | — | WO | claimed |
| EP-0189002-B1 | TREATMENT OF GASTROINTESTINAL DISORDERS USING 5-HT3 ANTAGONISTS | SANDOZ AG (CH) | 1993-03-03 | — | — | EP | claimed |
| EP-0340270-B1 | 5-HT 3? RECEPTOR ANTAGONISTS FOR TREATMENT OF COUGH AND BRONCHOCONSTRICTION | BEECHAM GROUP PLC (GB) | 1992-07-15 | — | — | EP | claimed |
| EP-0450757-A2 | Use of 5-hydroxytryptamine-antagonists in the treatment of mental disorders originating in childhood | GLAXO GROUP LIMITED (GB) | 1991-10-09 | — | — | EP | claimed |
| US-4910193-A | Containing a fused benzene ring structure | SANDOZ LTD. (CH) | 1990-03-20 | — | — | US | claimed |
| EP-0302008-A2 | 5HT-3 antagonists for prevention of dependence | SANDOZ AG (CH) | 1989-02-01 | — | — | EP | claimed |
| US-4789673-A | ANTISEROTONINE AGENTS | NOVARTIS AG (CH) | 1988-12-06 | — | — | US | claimed |
| US-11325904-B2 | Tropinol esters and related compounds to promote normal processing of APP | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2022-05-10 | — | — | US | disclosed |
| US-10981962-B2 | Modified ligand-gated ion channels and methods of use | HOWARD HUGHES MEDICAL INSTITUTE (US) | 2021-04-20 | — | — | US | disclosed |
| US-10449177-B2 | Methods of treating mild cognitive impairment (MCI) and related disorders | BUCK INSTITUTE FOR RESEARCH ON AGING (US) | 2019-10-22 | — | — | US | disclosed |
| EP-0313393-A2 | Benzoxazine compounds and pharmaceutical use thereof | Yoshitomi Pharmaceutical Industries, Ltd. (JP) | 1989-04-26 | — | — | EP | disclosed |
| US-4789673-A | ANTISEROTONINE AGENTS | NOVARTIS AG (CH) | 1988-12-06 | — | — | US | disclosed |
| EP-0189002-A2 | Treatment of gastrointestinal disorders using 5-HT3 antagonists | SANDOZ AG (CH) | 1986-07-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018008-A1 | Formulations of adenosine a1 agonists | ADORA1, ADORA3, ADORA2A | HTR3A 6/4885HTR3E 34/4885HTR3B 13/4885 |
| US-20020035057-A1 | Treatment of movement disorders by administration of 5-hydroxytryptamine receptor/alpha2 adrenergic receptor antagonist compositions | HTR2C, HTR2A, ADRA2C | HTR3A 8/4885HTR3E 28/4885HTR3B 11/4885 |
| US-10981962-B2 | Modified ligand-gated ion channels and methods of use | GRIK4, GRIK2, GRIK5 | HTR3A 1124/4885HTR3E 1597/4885HTR3B 1208/4885 |
| US-11325904-B2 | Tropinol esters and related compounds to promote normal processing of APP | APP, BACE1, APBA1 | HTR3A 1217/4885HTR3E 1403/4885HTR3B 1494/4885 |
| US-10449177-B2 | Methods of treating mild cognitive impairment (MCI) and related disorders | HNMT, NEFM, CHRM2 | HTR3A 53/4885HTR3E 99/4885HTR3B 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.